Application of Magnesium Valproate Combined with Ziprasidone in the Treatment of Bipolar Disorder
Objective To study the efficacy of magnesium valproate combined with ziprasidone in the treatment of bipolar disorder(BD).Methods A total of 78 BD patients from the Fifth People's Hospital of Kaifeng from March 2020 to February 2022 were selected and divided into single group(39 cases)and combined group(39 cases)according to random number table method.The single group was treated with magnesium valproate,and the combined group was treated with ziprasidone on the basis of single group.The therapeutic effects,levels of inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-4(IL-4),interleukin-1 β(IL-1β)],levels of neurotrophic factors[glial cell derived neurotrophic factor(GDNF),brain-derived neurotrophic factor(BDNF)],Hamilton depression rating scale(HAMD),Bech-Rafaelsen mania rating scale(BRMS)score and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of combined group[92.31％(36/39)]was higher than that of single group[64.10％(25/39)](P＜0.05).After treatment,the levels of TNF-α,IL-4 and IL-1 β in combination group were lower than those in single group(P＜0.05).After treatment,the levels of GDNF and BDNF in combination group were higher than those in single group(P＜0.05).After treatment,the BRMS score and HAMD score of the combined group were lower than those of the single group(P＜0.05).The incidence of adverse reactions in the combined group[12.82％(5/39)]was compared with the single group[10.26％(4/39)],with no statistical difference(P＞0.05).Conclusion Magnesium valproate combined with ziprasidone has a significant effect in the treatment of BD,which can reduce body inflammation,increase neurotrophic factor level,improve depression and mania symptoms in patients,and the treatment is safe.
万方数据
维普
